December 2, 2020 by Chain Drug Review
Bamlanivimab, CVS Health, Dr. Sree Chaguturu, Eli Lilly
Leading Headlines, Pharmacy
WOONSOCKET, R.I. — CVS Health was selected today by the U.S. Department of Health and Human Services (HHS), as part of Operation Warp Speed, to pilot the administration of a limited supply of bamlanivimab, a monoclonal antibody therapy, with eligible COVID-19 patients at-risk of severe infection or complications resulting from the virus. Under this pilot,
February 20, 2020 by Chain Drug Review
Dermira, Eli Lilly, Patrik Jonsson
Business, Leading Headlines, Pharmacy, Supplier News
INDIANAPOLIS — Eli Lilly and Co. announced the successful completion of its acquisition of Dermira. The acquisition expands Lilly’s immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic
September 13, 2018 by Chain Drug Review
diabetes research, Eli Lilly, Indiana Bioscience Research Institute, Indiana University School of Medicine, Lilly Diabetes Center of Excellence (LDCE), Ruth Gimeno
Supplier News
INDIANAPOLIS — Eli Lilly and Company and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine, have created the Lilly Diabetes Center of Excellence (LDCE), which aims to establish a nexus of strategically aligned basic diabetes research operations in Indianapolis. The LDCE will recruit high-potential and established principal investigators (PIs) who aim to pursue
September 4, 2018 by Chain Drug Review
Anne White, Eli Lilly, Eli Lilly Oncology, Sue Mahoney
Supplier News
INDIANAPOLIS — Eli Lilly Oncology will have a new president at the helm of the division. Industry veteran Anne White has been tapped to lead the division beginning Sept. 1. She replaced Sue Mahoney, whose last day with the company is today. White is currently the vice president of portfolio management of Chorus and Next Generation Research &
June 26, 2018 by Chain Drug Review
American Diabetes Association, diabetes, Eli Lilly, Tom Hardy
Pharmacy, Supplier News
ORLANDO, Fla. — Eli Lilly’s ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog. URLi is Lilly’s novel mealtime insulin currently in phase 3 development. The data was presented in
May 11, 2018 by Bill Schiffner
ARMO, Eli Lilly, Levi Garraway, Sue Mahony
Business, Leading Headlines, Supplier News
INDIANAPOLIS and REDWOOD CITY, Calif. — Eli Lilly and Company and ARMO BioSciences, Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate
April 23, 2018 by Chain Drug Review
baricitinib, Eli Lilly, Incyte Corp., rheumatoid arthritis, U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee
Pharmacy, Supplier News
INDIANAPOLIS — Eli Lilly and Incyte Corp. announced that the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the
April 17, 2018 by Chain Drug Review
Boehringer Ingelheim, diabetes, Eli Lilly, Jardiance, kidney disease
Pharmacy, Supplier News
RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Co. yesterday announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical
March 20, 2018 by Chain Drug Review
CVS Caremark, CVS Health, Derica Rice, Eli Lilly, Jonathan Roberts
Business, Featured Articles, Leading Headlines, Pharmacy, Retail News
NEW YORK — CVS Health has named former Eli Lilly and Co. chief financial officer Derica Rice as president of its CVS Caremark pharmacy benefit management unit. Plans call for Rice to take the helm at CVS Caremark on March 30, CVS said late Tuesday. The appointment was earlier reported by The Wall Street Journal.
February 12, 2018 by Greg Jacobson and Chain Drug Review
Alex Azar, Eli Lilly, Food and Drug Administration, HHS secretary, prescription drug prices, President Donald Trump, Secretary of Health and Human Services, State of the Union, Trump's State of the Union address
2018, Issue 02-12-2018, Issues, Leading Headlines, News, Pharmacy, Retail News
WASHINGTON — In his first State of the Union speech, President Donald Trump renewed his pledge to reduce prescription drug prices, days after a former big pharma executive was sworn in as Secretary of Health and Human Services. Trump had stunned the pharmaceutical industry during his 2016 campaign by declaring that drug manufacturers were “getting
January 25, 2018 by Chain Drug Review
Alex Azar, Chuck Grassley, Eli Lilly, Elizabeth Warren, HHS, HHS secretary, Ron Wyden, Todd Young, Tom Carper, Tom Price, U.S. Department of Health & Human Services
Leading Headlines, Pharmacy, Retail News
WASHINGTON — Former Eli Lilly and Co. executive Alex Azar has been confirmed by the Senate as the new secretary of the U.S. Department of Health & Human Services (HHS). Nominated for the HHS secretary post in November by President Donald Trump, Azar was approved by the Senate on Wednesday in a 55-43 vote, mainly
December 11, 2017 by Bill Schiffner
Affordable Care Act, Alex Azar, Eli Lilly, Health and Human Services Secretary, Patty Murray, Rand Paul, Senate health committee, Tom Price
2017, Issue 12-11-2017, Issues, News, Pharmacy, Retail News
WASHINGTON — Alex Azar, a former pharmaceutical executive named by President Trump to be the next Health and Human Services secretary, told senators at a full committee nomination hearing that making prescription drugs more affordable would be one of his top priorities. “Drug prices are too high,” Azar said to the Senate health committee at
November 14, 2017 by Chain Drug Review
Alex Azar, ational Community Pharmacists Association, B. Douglas Hoey, Bernie Sanders, Eli Lilly, HHS secretary, Lamar Alexander, Lilly USA, President Donald Trump, secretary of the U.S. Department of Health and Human Services, Tom Price
Featured Articles, Leading Headlines, Pharmacy, Retail News
WASHINGTON — Biopharmaceutical industry executive Alex Azar has been nominated as secretary of the U.S. Department of Health and Human Services (HHS) to fill the post vacated by Tom Price. Azar is currently founder and chairman of Seraphim Strategies LLC, an Indianapolis-based consultancy focused on the biopharma and health insurance industries, including biopharmaceutical sales, marketing, pricing,
October 30, 2017 by Chain Drug Review
David Ricks, Eli Lilly, Eli Lilly's diabetes business, Indianapolis insulin manufacturing facility, Maria Crowe
Business, Pharmacy, Supplier News
INDIANAPOLIS — Eli Lilly and Co. plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. Eli Lilly said the investment will be used to replace a current insulin vial-filling line. The move also stands to enable the company to meet rising demand for its insulins — including Humalog